%PDF-1.3
%
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
17 0 obj
<>>>/BBox[0 0 612 792]/Length 135>>stream
xM
ཧeٖ6'H1LB0b`ZT%$$7ĽT+ft# k%
qcJqA~KzX쐏*;VDZ9骿.:(
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
15 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/BBox[0 0 612 792]/Length 135>>stream
xM
ཧeٖ6'H1LB0b`ZT%$$7ĽT+ft# k%
qcJqA~KzX쐏*;VDZ9骿.:(
endstream
endobj
19 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
21 0 obj
<>>>/BBox[0 0 612 792]/Length 135>>stream
xM
ཧeٖ6'H1LB0b`ZT%$$7ĽT+ft# k%
qcJqA~KzX쐏*;VDZ9骿.:(
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 135>>stream
xM
ཧeٖ6'H1LB0b`ZT%$$7ĽT+ft# k%
qcJqA~KzX쐏*;VDZ9骿.:(
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
18 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
16 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 135>>stream
xM
ཧeٖ6'H1LB0b`ZT%$$7ĽT+ft# k%
qcJqA~KzX쐏*;VDZ9骿.:(
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
14 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
20 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
23 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2017-08-08T06:42:01-07:00
2017-07-15T06:41:24+05:30
application/pdf
JAYAO-2017-0037-ver9-Spathis_2P 1..5
uuid:1181a20b-ddef-49ef-9e7b-c533f1cf7d1b
uuid:864d2110-d076-4e96-88ea-cc41ec510fbd
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 BiUn)cT h
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 BiUn)sT
endstream
endobj
28 0 obj
<>stream
x+ |
endstream
endobj
29 0 obj
<>stream
xS**T0T0 Bih] 9S\ h
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 Bih]9K\ x
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 BiU9C\
endstream
endobj
35 0 obj
<>stream
/GS1 gs
BT
/F1 1 Tf
8.9663 0 0 8.9663 62.022 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
(Methods)Tj
/F9 1 Tf
0 -1.8336 TD
(Procedure)Tj
/F4 1 Tf
9.843 0 0 9.843 72 692.9006 Tm
[(Participants)-218.4(were)-214.9(recruited)-215.2(from)-212.9(three)-215.3(Teenage)-215.2(and)-217.6(Young)]TJ
-1.0137 -1.1116 TD
[(Adult)-191(Principal)-191(Treatment)-194.6(Centres)-189.5(\(TYA)-191.6(PTCs\))-191.7(in)-192.4(the)-188.9(United)]TJ
0 -1.1174 TD
[(Kingdom,)-508.7(and)-505.6(were)-508.7(required)-512.3(to)-503.4(have)-507.8(been)-513.6(diagnosed)-507.5(or)]TJ
0 -1.1116 TD
[(treated)-264.8(with)-259(cancer)-258.9(at)-256.9(age)-264.8(1324)-253.2(and)-257.9(to)-261.5(be)-256.8(1627)-258.9(at)-256.9(the)-258(time)]TJ
T*
[(of)-278.6(the)-281.1(survey)-7.5(.)]TJ
7.3823 0 0 6.5614 116.5606 653.4423 Tm
(18)Tj
9.843 0 0 9.843 72 638.0786 Tm
[(Electronic)-425(survey)-422.2(methods)-424.7(were)-422.3(used,)-423.5(following)-425.8(advice)]TJ
-1.0137 -1.1116 TD
[(from)-207.2(TYA)-202.1(PTC)-207(service)-206.9(users.)-205.5(After)-209.2(priming)-205(by)-203.8(email,)-202.8(poster,)]TJ
T*
[(and)-240.6(social)-245.1(media,)-248.8(a)-238.4(personalized)-248.3(email)-245.5(of)-244.1(invitation)-243.2(was)-241.3(sent)]TJ
T*
[(to)-336.4(potential)-335.3(participants,)-343(containing)-336.3(a)-336.3(unique)-336.2(token)-335.1(number)]TJ
0 -1.1174 TD
[(and)-396.1(links)-391.5(to)-394(the)-396.3(Participant)-396.1(Information)-394.8(Sheet)-393.7(and)-396.1(survey.)]TJ
0 -1.1116 TD
[(Nonresponders)-426(were)-416.5(ascertained)-426.9(by)-416.9(noting)-421.6(unused)-416.5(tokens,)]TJ
T*
[(and)-488.3(one)-488.3(reminder)-496.2(email)-487.4(was)-489(sent)-489.3(to)-491.9(nonresponders)-488.5(after)]TJ
0 -1.1174 TD
[(7)-254.5(days.)-250.7(Approval)-258.6(was)-252.8(given)-254.5(by)-249.9(the)-252.3(National)-254.3(Research)-261.9(Ethics)]TJ
0 -1.1116 TD
[(Service)-414.3(Committee)-413.5(East)-409.9(of)-411.1(EnglandCambr)-9.8(idgeshire)-409.7(and)]TJ
T*
[(Hertfordshire)-288.2(\(ref.)-279.6(15/EE/0037\).)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 62.022 516.6424 Tm
[(Outcome)-337.1(measures)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 500.2014 Tm
[(Demographic)-438.3(data)-415.8(were)-410.7(collected)-418.1(from)-414.5(both)-413.5(responders)]TJ
-1.0137 -1.1116 TD
[(and)-528.6(nonresponders.)-532.3(Participants)-535.2(completed)-533.3(two)-528.4(validated)]TJ
0 -1.1174 TD
[(measures.)-511.9(The)-512.5(PedsQL)]TJ
/F5 1 Tf
7.3823 0 0 6.5614 158.2866 482.6833 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 169.7952 478.2613 Tm
[(Multidimensional)-518(Fatigue)-511.2(Scale)]TJ
-10.9492 -1.1116 TD
[(\()-81.7(MFS\))-275.7(is)-267.1(a)-273(widely)-273.8(used)-270.3(18-item)-275.3(scale)-273.9(validated)-273(in)-273(both)-269.5(ado-)]TJ
T*
[(lescents)-259.8(and)-263.6(in)-255.8(young)-258.9(adults;)-256.7(scores)-261.9(are)-259(linearly)-264.9(transformed)]TJ
0 -1.1174 TD
[(to)-365.2(a)-365.1(0100)-362.6(scale,)-369.5(with)-368.4(lower)-364.7(scores)-365.6(representing)-373.8(worse)-364.4(fa-)]TJ
0 -1.1116 TD
(tigue.)Tj
7.3823 0 0 6.5614 84.3023 438.803 Tm
(19)Tj
9.843 0 0 9.843 93.4299 434.4377 Tm
[(The)-178.5(Quality)-177.2(of)-175(Life)-179.6(Visual)-181.5(Analog)-175.8(Scale)-181.8(\(QOL-VAS\))]TJ
-3.1909 -1.1116 TD
[(is)-422.6(a)-422.7(single-item)-424.9(measure)-421.1(of)-422.6(quality)-424(of)-422.6(life)-420.5(that)-420.5(captures)-426.9(a)]TJ
T*
[(clinically)-372.3(signicant)-364.7(change)-367.2(in)-365.2(quality)-366.4(of)-365(life)-362.9(more)-369.6(readily)]TJ
0 -1.1174 TD
[(than)-264.9(multiple-item)-261.8(measures.)]TJ
7.3823 0 0 6.5614 177.2787 405.9211 Tm
(20,21)Tj
9.843 0 0 9.843 72 390.6141 Tm
[(The)-414.6(severity)-391.3(of)-393.8(11)-393.9(symptoms)-391.2(and)-396.1(the)-390.5(impact)-396.3(of)-393.8(fatigue)]TJ
-1.0137 -1.1116 TD
[(were)-370.4(quantied)-375.2(using)-368.3(a)-370.9(5-item)-372.1(verbal)-371.9(rating)-370.9(scale:)-367.3()45(not)-367.4(at)]TJ
0 -1.1174 TD
[(all,)48.4()-352.4()50.8(a)-354.7(little)-354(bit,)49.5()-352.4()50.8(somewhat,)44.6()-352.4()50.8(quite)-359.3(a)-353.6(bit,)49.5()-352.4(and)-350()50.8(very)]TJ
25.504 36.217 TD
[(much.)46.3()-392.7(The)-391.6(successfulne)-11.6(ss)-387.7(of)-393.8(each)-399.6(treatment)-395.1(received)-393.7(for)]TJ
0 -1.1174 TD
[(fatigue)-223.4(was)-218.3(rated)-221(using)-218.5(a)-215.4(4-item)-216.6(scale:)-223.3()50.8(entirely)-219.9(successful,)44.8()]TJ
0 -1.1116 TD
[()45(somewhat)-279.2(successful,)44.8()-277.5()50.8(helped)-275.1(only)-281(a)-273(little,)44.7()-277.5(and)-275.2()50.8(no)-274(ef-)]TJ
T*
[(fect.)46.3()-387(A)-387.9()50.8(successfulness)-394.7(score)48.9()-387(for)-389.1(fatigue)-384.6(treatment)-389.4(was)]TJ
T*
[(generated)-429.4(by)-422.7(attributing)-422.8(0,)-425(1,)-419.2(2,)-425(and)-419.2(3)-427.3(t)0(o)-417(the)-425.1(ratings)-423.6()50.8(no)]TJ
0 -1.1174 TD
[(effect,)42.9()-254.5()50.8(helped)-257.8(only)-252.2(a)-255.7(little,)44.7()-254.5()50.8(somewhat)-261.9(successful,)44.8()-254.5(and)]TJ
0 -1.1116 TD
[()45(entirely)-433(successful,)44.8()-433(respectively,)-436.2(for)-429.5(each)-434.1(treatment)-435.5(re-)]TJ
T*
[(ceived)-257.9(and)-257.9(calculating)-259.2(a)-255.7(mean)-255.6(score.)-258.7(The)-253.3(former)-256.6(two)-257.7(ratings)]TJ
0 -1.1174 TD
[(dened)-348.6(an)-348.9(unsuccessful)-350.3(treatment)-349.1(and)-350(the)-344.4(latter)-349.1(two)-349.9(a)-347.8(suc-)]TJ
0 -1.1116 TD
[(cessful)-182.5(one.)-180.7(Selection)-180.7(of)-180.7(single)-180.6(or)-175(multiple)-184.5(best)-178.3(responses)-184.4(was)]TJ
T*
[(used)-212.7(for)-210.6(a)-209.6(number)-210.6(of)-209.5(further)-210.5(questions,)-216(including)-207.3(dening)-216.2(the)]TJ
0 -1.1174 TD
[(two)-194.4(symptoms)-195.3(most)-195.6(affecting)-197.9(daily)-191.2(life,)-193.5(views)-197.5(on)-192.3(the)-194.7(cause)-193.1(of)]TJ
0 -1.1116 TD
[(the)-263.8(fatigue,)-261.4(and)-263.6(details)-263.7(of)-261.4(fatigue)-263.7(treatments)-263.6(received.)]TJ
1.0137 -1.1116 TD
[(Participants)-327.9(indicating)-319.1(that)-322.6(fatigue)-321.3(had)-321.2(not)-320.2(affected)-324.5(them)]TJ
-1.0137 -1.1116 TD
[(over)-259(the)-252.3(past)-258.9(month)-254.5(only)-252.2(provided)-257.7(demographic)-258.9(information)]TJ
0 -1.1174 TD
[(and)-332.8(recorded)-329(the)-327.1(severity)-333.7(of)-324.7(the)-327.1(11)-330.5(symptoms,)-325.5(the)-327.1(2)-329.4(symp-)]TJ
0 -1.1116 TD
[(toms)-247.5(most)-247.5(affecting)-249.7(daily)-248.8(life,)-245.4(and)-246.4(the)-246.5(QOL-VAS.)-251.8(SPSS)-245.7(v22)]TJ
T*
[(was)-287.4(used)-281.8(for)-279.7(all)-281.2(analyses.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 313.0582 514.0345 Tm
(Results)Tj
/F4 1 Tf
9.843 0 0 9.843 323.0361 497.5936 Tm
[(The)-345.5(survey)-347.4(link)-344.5(was)-350.7(sent)-345.3(to)-342.2(197)-343.1(eligible)-351.5(patients)-345.4(and)-344.3(80)]TJ
-1.0137 -1.1116 TD
[(respon)-7.5(ded,)-295.9(equating)-299.4(to)-301.8(a)-296(41%)-303.9(response)-298.7(rate.)-304(Across)-302(all)-298.5(data)]TJ
T*
[(entry)-283.2(points,)-280.8(1.8%)-284.3(were)-284(missing.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 450.8786 Tm
[(Characteristics)-339.9(of)-330.4(participants)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 434.4377 Tm
[(There)-561.9(were)-554.7(two)-557.2(main)-559.9(differences)-563.8(between)-559.4(survey)-554.7(re-)]TJ
-1.0137 -1.1116 TD
[(sponders)-326.3(and)-327(nonresponders.)-324.9(First,)-325.6(no)-319(patients)-328.1(currently)-323.5(re-)]TJ
T*
[(ceiving)-355.9(cancer)-351.1(treatment)-354.8(participated.)-355.9(Second,)-352(signicantly)]TJ
0 -1.1174 TD
[(more)-237.2(females)-242.7(than)-236.1(males)-239.4(responded,)-240.1(with)-235.9(67%)-234.7(of)-238.3(responders)]TJ
0 -1.1116 TD
[(and)-482.5(47%)-482.4(of)-480.2(nonresponders)-482.7(being)-484.9(female.)-481.4(However,)-487.5(after)]TJ
T*
[(exclu)-8(ding)-304(patients)-316.6(in)-307.6(the)-309.9(nonresponder)-314.8(group)-310.7(still)-311.1(receiving)]TJ
0 -1.1174 TD
[(treatment,)-542.6(to)-538(compare)-536.5(responders)-542.8(and)-534.4(nonresponde)-8.5(rs)-531.9(off)]TJ
ET
62.022 343.956 490.167 .28348 re
f
62.022 104.258 490.167 .28348 re
f
62.022 305.348 490.167 .28345 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 141.959 349.6251 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F8 1 Tf
1.2496 0 TD
[(Comparison)-336.2(of)-337(Responder)-334.2(and)-332(Nonresponder)-338(Demographic)-337.2(Data)]TJ
/F6 1 Tf
2.4186 -2.8505 TD
(Responders)Tj
.8062 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F5 1 Tf
.668 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(80\))Tj
8.5802 2.027 TD
(All)Tj
-2.3783 -1.0135 TD
(nonresponders)Tj
1.192 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F5 1 Tf
.668 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(116\))Tj
/F4 1 Tf
7.0139 0 TD
(p)Tj
/F6 1 Tf
7.3837 0 0 6.5625 396.2267 315.9495 Tm
(a)Tj
9.845 0 0 9.845 438.7463 331.5401 Tm
(Nonresponders)Tj
-.7889 -1.0135 TD
[(excluding)-335.2(those)-334.4(on)]TJ
.2246 -1.0135 TD
[(treatment)-340.7(\()]TJ
/F4 1 Tf
4.5147 0 TD
(n)Tj
/F5 1 Tf
.6622 0 TD
(=)Tj
/F6 1 Tf
.7198 0 TD
(93\))Tj
/F4 1 Tf
4.4398 0 TD
(p)Tj
/F6 1 Tf
7.3837 0 0 6.5625 539.8865 315.9495 Tm
(a)Tj
/F4 1 Tf
9.845 0 0 9.845 62.022 292.9322 Tm
[(Off/on)-335.2(treatment,)]TJ
/F6 1 Tf
.9905 -1.0135 TD
(n)Tj
/F4 1 Tf
.835 0 TD
[(\(missing)-337.3(data\))]TJ
11.7359 1.0135 TD
[(70/0)-338.1(\(10\))-5330.6(90/23)-333.4(\(3\))]TJ
/F5 1 Tf
18.7325 0 TD
(<)Tj
/F7 1 Tf
.5528 0 TD
(0.001)Tj
/F4 1 Tf
7.3837 0 0 6.5625 407.5652 297.2975 Tm
(b)Tj
9.845 0 0 9.845 433.7574 292.9322 Tm
[(90/0)-338.1(\(3\))-6711.7(NA)]TJ
-37.7588 -2.027 TD
[(Age)-333.2(at)-337.3(survey)-335.2(in)-330.4(years,)]TJ
.9905 -1.0135 TD
[(mean)-335.7(\(SD,)-335.2(range\))]TJ
12.6055 1.0135 TD
[(22.1)-334.6(\(2.7,)-332.2(1727\))-2533.9(21.3)-328.8(\(2.7,)-338(1627\))-2551.2(0.06)]TJ
7.3837 0 0 6.5625 402.633 277.3416 Tm
(c)Tj
9.845 0 0 9.845 434.0975 272.9763 Tm
[(21.5)-334.6(\(2.6,)-332.2(1627\))-2286.3(0.21)]TJ
7.3837 0 0 6.5625 543.5715 277.3416 Tm
(c)Tj
9.845 0 0 9.845 62.022 253.0771 Tm
[(Age)-333.2(at)-337.3(diagnosis)-332.6(in)-336.2(years,)]TJ
.9905 -1.0135 TD
[(mean)-335.7(\(SD,)-335.2(range\))]TJ
12.6055 1.0135 TD
[(18.9)-334.6(\(3.1,)-332.2(1224\))-2533.9(18.2)-328.8(\(3.3,)-338(924\))-3051.2(0.12)]TJ
7.3837 0 0 6.5625 402.633 257.4424 Tm
(c)Tj
9.845 0 0 9.845 434.0975 253.0771 Tm
[(18.0)-334.6(\(3.2,)-332.2(1224\))-2286.3(0.06)]TJ
7.3837 0 0 6.5625 543.5715 257.4424 Tm
(c)Tj
9.845 0 0 9.845 62.022 233.1212 Tm
[(Months)-335(since)-335.5(diagnosis,)]TJ
.9905 -1.0077 TD
[(median)-337.9(\(IQR\))]TJ
13.3541 1.0077 TD
[(31)-336(\(1849\))-5114.8(31)-330.2(\(1458\))-4389.2(0.85)]TJ
7.3837 0 0 6.5625 402.633 237.4866 Tm
(d)Tj
9.845 0 0 9.845 441.4676 233.1212 Tm
[(37)-336(\(2161\))-4118.5(0.19)]TJ
7.3837 0 0 6.5625 543.5715 237.4866 Tm
(d)Tj
9.845 0 0 9.845 62.022 213.222 Tm
[(Months)-335(since)-335.5(last)-333.5(treatment,)]TJ
.9905 -1.0135 TD
[(median)-337.9(\(IQR\))]TJ
13.3541 1.0135 TD
[(18)-336(\(1032\))-5114.8(18)-330.2(\(546\))-4889.2(0.50)]TJ
7.3837 0 0 6.5625 402.633 217.5873 Tm
(d)Tj
9.845 0 0 9.845 441.4676 213.222 Tm
[(27)-336(\(1152\))]TJ
/F7 1 Tf
8.6205 0 TD
(0.05)Tj
/F4 1 Tf
7.3837 0 0 6.5625 543.5715 217.5873 Tm
(d)Tj
9.845 0 0 9.845 62.022 193.2661 Tm
[(Months)-335(treatment)-336.6(duration,)]TJ
.9905 -1.0077 TD
[(median)-337.9(\(IQR\))]TJ
13.8551 1.0077 TD
[(8)-335(\(425\))-7422.9(NA)-5958(NA)-4443.5(6)-335(\(49\))]TJ
/F7 1 Tf
32.317 0 TD
(0.006)Tj
/F4 1 Tf
7.3837 0 0 6.5625 548.5038 197.6315 Tm
(d)Tj
9.845 0 0 9.845 62.022 173.3669 Tm
(Gender,)Tj
/F6 1 Tf
3.53 0 TD
(n)Tj
/F4 1 Tf
.501 0 TD
[(,)-331.6(male)-335.9(\(%\))-5941(26)-336(\(33\))-6614.8(62)-330.2(\(53\))]TJ
/F7 1 Tf
28.8158 0 TD
(0.005)Tj
/F4 1 Tf
7.3837 0 0 6.5625 407.5652 177.7323 Tm
(b)Tj
9.845 0 0 9.845 441.4676 173.3669 Tm
[(44)-336(\(47\))-5618.5(0.06)]TJ
7.3837 0 0 6.5625 543.5715 177.7323 Tm
(b)Tj
9.845 0 0 9.845 62.022 160.3842 Tm
(Diagnosis,)Tj
/F6 1 Tf
4.5838 0 TD
(n)Tj
/F4 1 Tf
.835 0 TD
(\(%\))Tj
-4.4168 -1.0077 TD
[(Leukemia)-9325.5(20)-336(\(25\))-6614.8(20)-330.2(\(17\))-5889.2(0.44)]TJ
7.3837 0 0 6.5625 402.633 154.8283 Tm
(b)Tj
9.845 0 0 9.845 441.4676 150.463 Tm
[(12)-336(\(13\))-5618.5(0.11)]TJ
7.3837 0 0 6.5625 543.5715 154.8283 Tm
(b)Tj
9.845 0 0 9.845 71.8866 140.485 Tm
[(Lymphoma)-8719.5(35)-336(\(44\))-6614.8(53)-330.2(\(46\))-11584.4(50)-336(\(54\))]TJ
0 -1.0135 TD
[(Osteosarcoma/Ewings)-4560.4(6)-335(\(8\))-7615.8(9)-329.2(\(8\))-12585.4(3)-335(\(3\))]TJ
T*
[(Brain)-335.5(neoplasm)-7440(1)-335(\(1\))-7615.8(8)-329.2(\(7\))-12585.4(6)-335(\(6\))]TJ
0 -1.0077 TD
[(Other)-11063.5(18)-336(\(23\))-6614.8(26)-330.2(\(22\))-11584.4(22)-336(\(24\))]TJ
6.5633 0 0 5.8334 70.0157 96.3779 Tm
(a)Tj
/F6 1 Tf
8.7511 0 0 8.7511 72.9637 92.4661 Tm
(p)Tj
/F4 1 Tf
.4988 0 TD
[(-Values)-335.5(comparing)-330.1(preceding)-333.7(column)-333.8(of)-333.1(nonresponders)-331(with)-332(responders)-334.4(and)-334.6(signicant)]TJ
/F6 1 Tf
36.091 0 TD
(p)Tj
/F4 1 Tf
.4988 0 TD
[(-values)-333.2(in)-333.3(bold.)]TJ
6.5633 0 0 5.8334 70.0157 87.3637 Tm
(b)Tj
8.7511 0 0 8.7511 73.3039 83.5086 Tm
(Fisher)Tj
6.5633 0 0 5.8334 95.1307 87.3637 Tm
()Tj
8.7511 0 0 8.7511 97.3417 83.5086 Tm
[(s)-334.1(Exact)-334.7(Test.)]TJ
6.5633 0 0 5.8334 70.0157 78.4063 Tm
(c)Tj
8.7511 0 0 8.7511 72.9637 74.5512 Tm
[(Independent)-331.4(samples)]TJ
/F6 1 Tf
8.843 0 TD
(t)Tj
/F4 1 Tf
.285 0 TD
(-test.)Tj
6.5633 0 0 5.8334 70.0157 69.4488 Tm
(d)Tj
8.7511 0 0 8.7511 73.3039 65.537 Tm
[(MannWhitney)-332.9(U)-331.5(test.)]TJ
-.3757 -1.0236 TD
[(IQR,)-332.8(interquartile)-335.5(range;)-329.5(SD,)-332.8(standard)-338.6(deviation.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
46.7706 0 TD
[(SPATHIS)-337.3(ET)-338.7(AL.)]TJ
ET
endstream
endobj
48 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 480.5857 Tm
0 0 0 rg
0 Tc
0 Tw
[(treatment,)-335.2(there)-336.2(was)-327.7(no)-330.5(longer)-330.4(evidence)-336.1(of)-330.5(a)-330.6(gender)-331.4(differ-)]TJ
0 -1.1174 TD
[(ence)-284.4(between)-282.9(the)-281.1(two)-286.5(groups)-277.1(\(Table)-286.7(1\).)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 59.7543 445.6062 Tm
[(Impact)-333.2(of)-336.7(fatigue)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 429.1653 Tm
[(Fatigue)-303.9(was)-275.8(the)-281.1(most)-276.3(prevalent)-284.3(symptom,)-278.5(experienced)-283(by)]TJ
-1.0137 -1.1116 TD
[(85%)-177.2(\(68/80\))-180.6(during)-173.7(the)-177.4(preceding)-180.5(month)-173.9(\(Fig.)-180.6(1\).)-172.6(Fatigue)-177.2(was)]TJ
T*
[(ranked)-481.2(as)-475.5(more)-479.1(severe)-482.2(than)-478(each)-480.2(of)-474.5(the)-482.6(other)-473.3(symptoms)]TJ
0 -1.1174 TD
[(\(Wilcoxon)-497.4(signed-rank)-492.4(test;)]TJ
/F6 1 Tf
12.1703 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.001,)-489.3(except)-494(anxiety)]TJ
/F6 1 Tf
9.5496 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
-23.7761 -1.1116 TD
[(0.007\).)-213.9(The)-218.8(mean)-215.3(fatigue)-217.6(severity)-212.8(of)-215.3(the)-211.9(fatigued)-218.7(participants)]TJ
T*
[(was)-195.2(44.3)-185.3(\(standard)-190.7(devia)-8(tion)-189([SD])-189.4(20.5\).)-189.8(Fatigue)-188.7(severity)-189.7(was)]TJ
0 -1.1174 TD
[(worse)-560.2(more)-553.9(than)-558.6(1)-554(year)-553.9(after)-555.1(the)-557.5(last)-558.6(cancer)-558.4(treatment)]TJ
0 -1.1116 TD
.0875 Tc
(\(M)Tj
/F5 1 Tf
1.4687 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.72 0 TD
[(39.0,)-649.5(SD)]TJ
/F5 1 Tf
4.0894 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(19.7\),)-650.6(compared)-652.8(to)]TJ
/F5 1 Tf
9.0255 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(1)-651.9(year)-651.8(\()-81.7(M)]TJ
/F5 1 Tf
4.9994 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(53.8,)Tj
-22.2958 -1.1116 TD
(SD)Tj
/F5 1 Tf
1.4399 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(19.7;)-232.6(independent)-234.7(samples)]TJ
/F6 1 Tf
10.857 0 TD
(t)Tj
/F4 1 Tf
.2822 0 TD
[(-test,)-234.8(t\(56\))]TJ
/F5 1 Tf
4.3255 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(2.8,)Tj
/F6 1 Tf
1.7279 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.007\).)Tj
-21.4607 -1.1174 TD
[(Fatigue)-470.9(was)-471.7(worse)-473.8(in)-468.9(females)-473.1(\()-81.7(M)]TJ
/F5 1 Tf
14.67 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(39.6,)-465.2(SD)]TJ
/F5 1 Tf
3.9051 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(19.3\))-468.6(than)]TJ
-20.015 -1.1116 TD
[(males)-371.9(\()-81.7(M)]TJ
/F5 1 Tf
4.1815 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(55.6,)-367.3(SD)]TJ
/F5 1 Tf
3.8072 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(19.6;)-365.1(t\(66\))]TJ
/F5 1 Tf
4.5099 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(3.1,)Tj
/F6 1 Tf
1.8661 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(0.003\),)-369.4(but)-360.5(was)]TJ
-17.8954 -1.1116 TD
[(not)-360.5(associated)-361.1(with)-356.9(other)-352.4(demographic)-362.5(variables,)-356.7(including)]TJ
T*
[(cancer)-506.6(type)-506.8(or)-503.3(treatment)-504.6(duration.)-503.2(In)-503.3(a)-503.3(linear)-504.5(regression)]TJ
0 -1.1174 TD
[(analysis,)-273.6(anorexia)-277.3(and)-269.4(low)-269.2(mood)-270.6(explained)-272.9(50%)-269.3(of)-267.1(the)-275.3(vari-)]TJ
0 -1.1116 TD
[(ation)-254.6(in)-255.8(fatigue)-257.9(severity)-258.8(\(adjusted)-254.2(R)]TJ
7.3823 0 0 6.5614 201.2598 280.1196 Tm
(2)Tj
9.843 0 0 9.843 207.4393 275.7543 Tm
[(0.50,)-252.1(F)-254.4(change)]TJ
/F5 1 Tf
6.0707 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(26.60,)Tj
/F6 1 Tf
-21.7947 -1.1116 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.001\).)-415.5(Gender)-418.7(no)-411.1(longer)-416.8(had)-419.2(a)-417(statistically)-421.5(signicant)]TJ
-1.3881 -1.1174 TD
[(relationship)-240.5(with)-235.9(fatigue)-240.6(after)-238.3(adjusting)-235.9(for)-239.4(anorexia)-237(and)-234.9(low)]TJ
0 -1.1116 TD
[(mood.)-170.3(Fatigue)-171.4(\()-87.5(MFS\))-166.2(was)-172.2(an)-170.4(independent)-171.4(predictor)-173.7(of)-169.2(quality)]TJ
T*
[(of)-468.7(life,)-470(after)-468.7(adjusting)-466.3(for)-464(the)-471.1(potential)-467.8(confounders,)-466.9(low)]TJ
0 -1.1174 TD
[(mood,)-550.5(and)-551.6(anorexia)-553.8(\(adjusted)-553.7(R)]TJ
7.3823 0 0 6.5614 197.4047 225.3543 Tm
(2)Tj
9.843 0 0 9.843 206.5322 220.9322 Tm
[(0.42,)-551.6(F)-548.1(change)]TJ
/F5 1 Tf
6.664 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(7.13,)Tj
/F6 1 Tf
-22.2958 -1.1116 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.01\).)Tj
-.3744 -1.1116 TD
[(All)-275.1(participants,)-279.6(including)-276.4(those)-271.6(not)-274.1(experiencing)-283.1(fatigue,)]TJ
-1.0137 -1.1174 TD
[(were)-272.5(asked)-272.6(which)-272.6(2)-266(out)-268.4(of)-267.1(11)-272.9(symptoms)-270.2(most)-270.5(affected)-272.7(daily)]TJ
0 -1.1116 TD
[(life.)-256.9(Fatigue)-252(was)-252.8(chosen)-256.4(more)-248.7(often)-254.4(than)-253.4(any)-252.1(other)-248.7(symptom)]TJ
T*
[(\(Wilcoxon)-255.5(signed-rank)-256.2(tests,)]TJ
/F5 1 Tf
11.8074 0 TD
(-)Tj
/F4 1 Tf
.5529 0 TD
(7.87)Tj
/F5 1 Tf
1.9986 0 TD
(<)Tj
/F4 1 Tf
.8064 0 TD
(Z)Tj
/F5 1 Tf
.864 0 TD
.2544 Tc
(<-)Tj
/F4 1 Tf
1.3535 0 TD
0 Tc
[(4.99,)-252.1(all)]TJ
/F6 1 Tf
3.5134 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
(-values)Tj
/F5 1 Tf
-21.3973 -1.1116 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(0.001\).)-346.4(The)-351.2(greatest)-346.4(impact)-350.2(of)-347.7(fatigue)-350.1(on)-342(aspects)-350.8(of)-347.8(daily)]TJ
-.5529 -1.1174 TD
[(life)-288(was)-293.1(on)-284.4(the)-286.8(ability)-285.9(to)-290.3(exercise,)-287.5(with)-287.8(74%)-286.6(\(50/68\))-290(experi-)]TJ
0 -1.1116 TD
[(encing)-256.7()50.8(somewhat,)44.6()-248.7()50.8(quite)-249.9(a)-249.9(bit,)49.5()-254.5(o)0(r)-249.8()50.8(very)-248.5(much)44()-248.7(impact.)]TJ
T*
[(Attending)-294.6(school)-289.9(or)-284.4(work)-293.2(was)-287.4(hindered)-293.5(for)-285.5(65%)-292.4(and)-286.7(social-)]TJ
0 -1.1174 TD
[(izing)-283.4(for)-285.5(56%.)-284.3(Forty-ve)-281.5(percent)-287.8(of)-284.4(participants)-287.7(\(29/64\))-284.2(felt)]TJ
0 -1.1116 TD
[(that)-236.2(their)-231.5(fatigue)-234.9(made)-232.6(the)-235(person)-232.2(most)-230.2(involved)-234.9(in)-227(their)-237.3(care)]TJ
T*
[()50.8(somewhat,)44.6()-208.4()50.8(quite)-209.6(a)-203.8(bit,)49.5()-208.4(o)0(r)-203.8()50.8(very)-208.2(much)44()-202.7(upset,)-205.9(42%)-211.7(\(27/)]TJ
0 -1.1174 TD
[(64\))-412.2(felt)-414.7(it)-411.4(caused)-413.1(frustration,)-414.2(and)-413.4(41%)-407.5(\(26/64\))-411(believed)-415.7(it)]TJ
0 -1.1116 TD
[(limited)-258.3(rest)-253.1(time.)-258.2(Only)-253.1(13%)-252(\(8/64\))-254.3(thought)-255.6(that)-253.5(there)-255.6(was)-252.8(no)]TJ
T*
[(negative)-283.3(impact.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 310.8472 423.7227 Tm
[(Fatigue)-333.7(management)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 407.2818 Tm
[(A)-278.4(minority)-263.8(of)-261.4(fatigued)-264.8(participants)-264.7(\(19%,)-262.3(13/68\))-265.9(believed)]TJ
-1.0137 -1.1116 TD
[(that)-368.7()50.8(something)-376.3(could)-369.7(be)-372(done)45.2()-369.7(about)-369.7(fatigue,)-376.6(with)-368.4(many)]TJ
0 -1.1174 TD
[(\(38%,)-302.6(26/68\))-306.2(believing)-312.1(it)-307.7(to)-301.8(be)-308.6(a)-307.5(symptom)-303.8(one)-309.7()50.8(has)-304.8(to)-307.6(live)]TJ
0 -1.1116 TD
[(with.)47.6()-381.2(Although)-390.1(65%)-384.5(\(44/68)-6.7(\))-381.2(had)-390.4(talked)-389.3(to)-382.5(a)-388.2(health)-389.3(carer)]TJ
T*
[(about)-490.6(feeling)-499.8(fatigued;)-496.4(the)-494.2(most)-495.2(common)-494.1(reason)-498.3(for)-492.8(not)]TJ
0 -1.1174 TD
[(talking)-262.7(was)-258.6(a)-261.4(belief)-262.6(that)-265(nothing)-261.4(could)-260.2(be)-262.5(done)-259(\(60%,)-262.3(9/15\).)]TJ
1.0137 -1.1116 TD
[(Forty-one)-275.9(percent)-282(\(28/68\))-272.7(of)-278.6(the)-275.3(fatigued)-282.1(participants)-282(had)]TJ
-1.0137 -1.1116 TD
[(not)-423.9(been)-432.9(recommended)-428.1(fatigue)-430.7(treatments.)-434(The)-426.1(remaining)]TJ
T*
[(participants)-374.1(had)-367.3(been)-375.4(recommended)-376.3(a)-365.1(median)-373.2(of)-370.8(2.5)-368.5(treat-)]TJ
0 -1.1174 TD
[(ments)-336.1(\(range)-342.9(17\),)-336.1(most)-339.6(commonly)-335.1(advice)-344.3(to)-336.4(exercise)-341.7(\(27/)]TJ
0 -1.1116 TD
[(40\))-314.3(or)-319(to)-319.1(rest)-316.5(and)-321.2(relax)-319(\(22/40\).)-316.5(There)-320(was)-321.9(no)-313.2(difference)-326.7(in)]TJ
T*
[(fatigue)-275.2(severity)-276.1(\()-87.5(MFS\))-275.7(between)-277.1(those)-271.6(recommended)-284.2(fatigue)]TJ
0 -1.1174 TD
[(treatments)-390.3(and)-390.4(those)-392.5(not.)-392.8(Only)-385.5(blood)-391.5(transfusion)-393.2(was)-391(per-)]TJ
0 -1.1116 TD
[(ceived)-344.3(as)-348.8(successful)-348.1(more)-340.8(often)-346.6(than)-345.5(unsuccessful)-350.3(\(Fig.)-341.8(2\).)]TJ
T*
[(Successfulness)-226.6(of)-226.8(fatigue)-223.4(treatment)-228.1(was)-224(lower)-226.5(in)-221.2(participants)]TJ
0 -1.1174 TD
[(more)-415.7(than)-420.4(1)-415.8(year)-421.4(from)-420.3(last)-420.3(cancer)-420.2(treatment)-423.9(compared)-422.4(to)]TJ
0 -1.1116 TD
(those)Tj
/F5 1 Tf
2.396 0 TD
(<)Tj
/F4 1 Tf
.5472 0 TD
[(1)-283.3(year)-283.2(from)-282(treatment)-279.9([t\(30\))]TJ
/F5 1 Tf
11.554 0 TD
.1622 Tc
(=-)Tj
/F4 1 Tf
1.2671 0 TD
0 Tc
(2.93,)Tj
/F6 1 Tf
2.2808 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.006].)Tj
-18.4195 -1.1116 TD
[(All)-246.3(participants,)-250.8(irrespective)-254.1(of)-244.1(whether)-252.9(they)-247.6(had)-246.4(received)]TJ
-1.0137 -1.1174 TD
[(fatigue)-332.8(treatment,)-329.4(were)-330.1(asked)-335.9(what)-329.1(they)-328.2(personally)-330.2(thought)]TJ
0 -1.1116 TD
[(was)-235.5(the)-240.7(single)-238.2(best)-235.9(treatment.)-237.3(Most)-241.4(chose)-238(exercise)-238(\(24%,)-239.3(14/)]TJ
T*
[(58\),)-392.6(followed)-397(by)-393.9(diet/nutrition)-397.6(\(12%,)-394.8(7/58\),)-394.9(rest/relaxation)]TJ
T*
[(\(12%,)-423.6(7/58\),)-423.7(naps/sleeping)-426.8(\(10%,)-423.6(6/58\),)-423.7(blood)-426.1(transfusion)]TJ
0 -1.1174 TD
[(\(7%,)-474.3(4/58\),)-475.6(complementary)-482.4(therapies)-480(\(5%,)-474.3(3/58\),)-475.6(physio-)]TJ
0 -1.1116 TD
[(therapy)-229(\(3%,)-232.4(2/58\),)-233.7(and)-229.1(fatigue)-234.9(group)-230.1(attendance)-236(\(3%,)-232.4(2/58\).)]TJ
T*
[(Thirteen)-300.5(of)-295.9(the)-298.3(16)-295.9(participants)-299.2(who)-297.9(recommended)-301.4(an)-297.1(active)]TJ
0 -1.1174 TD
[(treatment)-429.7(\(exercise)-434.9(or)-422.6(physiotherapy\))-432.5(had)-430.7(received)-428.3(an)-429.6(ac-)]TJ
0 -1.1116 TD
[(tive)-276.5(treatment)-279.9(themselves;)-276(those)-277.3(who)-274.9(had)-275.2(received)-278.5(an)-274.1(active)]TJ
T*
[(treatment)-193.5(were)-191.9(more)-185.3(likely)-192.5(to)-192.4(recommend)-188.6(an)-193.4(active)-188.9(treatment)]TJ
0 -1.1174 TD
[(as)-279.6(being)-277.5(better)-279.9(than)-276.4(a)-278.7(rest-focused)-281.3(treatment)-279.9(\(Fishers)-281.3(Exact)]TJ
0 -1.1116 TD
(Test,)Tj
/F6 1 Tf
2.2405 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(0.001\).)-265.8(However,)-262.9(no)-261.4(evidence)-267(was)-264.3(found)-258.9(that)-265(those)]TJ
-3.6228 -1.1116 TD
[(who)-372.8(had)-373.1(received)-376.4(a)-376.6(rest-focused)-379.2(treatment)-372.1(\(rest/r)-8.8(elaxation,)]TJ
T*
[(naps/sleeping,)-315(or)-307.4(complementary)-315.4(therapy\))-310.7(were)-312.8(more)-306.3(likely)]TJ
0 -1.1174 TD
[(to)-278.8(recommend)-286.5(a)-278.7(rest-focused)-287.1(treatment)-285.7(\()]TJ
/F6 1 Tf
16.5649 0 TD
(p)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.62\).)Tj
ET
q
1 i
60.321 732.245 m
298.261 732.245 l
298.261 522.425 l
60.321 522.425 l
W n
q
238.023 0 0 209.82 60.321 522.425 cm
/Im1 Do
Q
Q
BT
/F7 1 Tf
9.845 0 0 9.845 96.0945 505.644 Tm
[(FIG.)-336.7(1.)]TJ
/F4 1 Tf
4.1174 0 TD
[(Symptom)-331.7(prevalence)-338.4(bar)-332.4(chart.)]TJ
ET
q
1 i
311.414 732.245 m
549.354 732.245 l
549.354 490.564 l
311.414 490.564 l
W n
q
238.023 0 0 241.682 311.414 490.564 cm
/Im2 Do
Q
Q
BT
/F7 1 Tf
9.845 0 0 9.845 310.8472 473.7825 Tm
[(FIG.)-307.9(2.)]TJ
/F4 1 Tf
4.0886 0 TD
[(Stacked)-304.1(bar)-309.3(chart)-306.9(showing)-307.2(successfulness)-311.5(of)-307.2(each)]TJ
-4.0886 -1.0077 TD
[(fatigue)-332.1(treatment.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(CANCER-RELATED)-345.8(FATIGUE)-331.2(IN)-335.1(AYA)]TJ
6.4556 0 0 6.4556 219.4582 749.7069 Tm
(S)Tj
8.9663 0 0 8.9663 544.9889 749.7069 Tm
(3)Tj
ET
endstream
endobj
50 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳf